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Abstract
Background: The aim of this study was to clarify the role of global hypomethylation of repetitive elements in
determining the genetic and clinical features of multiple myeloma (MM).
Methods: We assessed global methylation levels using four repetitive elements (long interspersed nuclear
element-1 (LINE-1), Alu Ya5, Alu Yb8, and Satellite-a) in clinical samples comprising 74 MM samples and 11 benign
control samples (7 cases of monoclonal gammopathy of undetermined significance (MGUS) and 4 samples of
normal plasma cells (NPC)). We also evaluated copy-number alterations using array-based comparative genomic
hybridization, and performed methyl-CpG binding domain sequencing (MBD-seq).
Results: Global levels of the repetitive-element methylation declined with the degree of malignancy of plasma
cells (NPC>MGUS>MM), and there was a significant inverse correlation between the degree of genomic loss and
the LINE-1 methylation levels. We identified 80 genomic loci as common breakpoints (CBPs) around commonly lost
regions, which were significantly associated with increased LINE-1 densities. MBD-seq analysis revealed that average
DNA-methylation levels at the CBP loci and relative methylation levels in regions with higher LINE-1 densities also
declined during the development of MM. We confirmed that levels of methylation of the 5’ untranslated region of
respective LINE-1 loci correlated strongly with global LINE-1 methylation levels. Finally, there was a significant
association between LINE-1 hypomethylation and poorer overall survival (hazard ratio 2.8, P = 0.015).
Conclusion: Global hypomethylation of LINE-1 is associated with the progression of and poorer prognosis for MM,
possibly due to frequent copy-number loss.
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Background
Multiple myeloma (MM) is a malignant plasma-cell
tumor characterized by various and frequent chromoso-
mal aberrations. Representative examples of these aberra-
tions are loss of chromosome 13, hyperdiploidy, and
translocations involving the immunoglobulin heavy chain
(IGH) locus situated at 14q32.33. Several studies have
shown that these genetic changes are associated with the
clinical features of MM, including its prognosis [1-7].
In addition to such genetic changes, recent studies have
begun to shed light on the role of epigenetic alterations
in the pathogenesis of MM. One of the earliest reports of
epigenetic aberrations in MM was of DNA hypermethy-
lation in the promoter CpG islands of p15 and p16
[8-10]. Tumor-specific hypermethylation has also been
found in the promoter regions of various tumor suppres-
sors and other tumor-related genes, including BNIP3,
DAPK and RASD1, which are associated with prognosis
and drug resistance in MM [11-14]. Unexpectedly, how-
ever, recent advances in genome-wide analysis revealed
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that the number of methylated genes declines markedly
with the progression of malignant transformation of
plasma cells [15,16]. In addition, histone modifications
are also involved in the pathogenesis of MM, and are
associated with aberrant gene expression or important
translocations such as t(4;14) [17,18].
Global DNA hypomethylation is also known to be a
common epigenetic alteration in tumor cells [19], and is
tightly linked to hypomethylation of DNA repetitive ele-
ments [20]. Some repetitive elements, such as long inter-
spersed nuclear element-1 (LINE-1) and Alu, are capable
of retrotransposition; that is, they are able to insert them-
selves into genomic sequences, which can cause genomic
instabilities leading to genome-wide mutations, insertions,
and deletions [21]. Moreover, because these transposi-
tional activities are usually silenced in association with
DNA methylation, global hypomethylation is thought to
promote the initiation and progression of tumorigenesis
through the aberrant activation of repetitive elements [21].
To date, there have been numerous studies demonstrating
hypomethylation of repetitive elements in malignancies
[22]. In particular, hypomethylation of LINE-1 is report-
edly associated with malignancy, poor prognosis, and
chromosomal instability in various types of tumors
[23-27].
Our aim in the present study was to clarify the role of
global hypomethylation of repetitive elements in determin-
ing the genetic and clinical features of MM. To address
this issue, we measured the methylation levels of four
repetitive elements, and assessed their association with
genome-wide copy-number alterations. This integrative
analysis of the genetic, epigenetic, and clinical characteris-
tics of MM enabled us to discover a strong association
between LINE-1 hypomethylation and copy-number loss
and poor prognosis in patients with MM.
Materials and Methods
Ethics approval
This study was approved by the institutional review
board at Sapporo Medical University (Ethics Committee)
and conforms to the tenets of the Declaration of Helsinki.
informed consent was obtained prior to sample
collection.
Patients and sample preparation
Bone-marrow aspirates were collected between 2007 and
2010 at the Department of Hematology (Hiroshima Red
Cross and Atomic-Bomb Survivors Hospital) and in the
1st Department of Internal Medicine (Sapporo Medical
University Hospital) from patients with MM (n = 74),
patients with monoclonal gammopathy of undetermined
significance (MGUS, n = 7), and patients with non-
plasma-cell tumors with normal plasma cells (NPC, n = 4).
We isolated mononuclear cells from the samples using
density-gradient separation (Ficoll-Paque; StemCell Tech-
nologies Inc., Vancouver, Canada), and then separated the
CD138-positive cells using CD138 polymer particles
(CD138 MicroBeads; Miltenyi Biotec GmBH, Gladbach,
Germany) to isolate the plasma cells. Finally, we extracted
the genomic DNA from the CD138-positive cells
(QIAamp DNA Blood Mini Kit; Qiagen Inc., Valencia,
CA, USA).
DNA-methylation analysis
Bisulfite conversion of genomic DNA was carried out (Epi-
Tect Bisulfite Kit; Qiagen Inc.). We then used PCR to
amplify sequences containing CpG sites in the promoter
regions of LINE-1, Alu Yb8, Alu Ya5, and Satellite-a on
chromosome 1 (Sat-a), as described previously [27]. The
biotinylated PCR products were purified, made single-
stranded, and used as templates in a pyrosequencing reac-
tion according to the manufacturer’s instructions (Qiagen
Inc.). Briefly, the PCR products were bound to streptavi-
din-conjugated beads (Streptavidin Sepharose HP Beads;
Amersham Biosciences Inc., Piscataway, NJ, USA), and
were then purified, washed, and denatured with 0.2 mol/L
NaOH solution. After addition of 0.3 μmol/L sequencing
primer to the purified PCR products, pyrosequencing was
carried out using an appropriate system (PSQ96MA) and
software (Pyro Q-CpG) (both Biotage AB, Uppsala, Swe-
den). The primer sequences used in this study are listed in
Additional file 1, Table S1.
Array comparative genomic hybridization
Array comparative genomic hybridization (aCGH) analy-
sis was performed according to the manufacturer’s
instructions (Agilent Technologies Inc., Wilmington, DE,
USA). We first used the restriction enzymes AluI and
RsaI to digest 500 ng each of genomic DNA from 67
MM and 6 MGUS samples as well as an aliquot of gen-
der-matched reference DNA (Promega Corp., Madison,
WI, USA). We then labeled (Genomic DNA Enzymatic
Labeling Kit; Agilent Technologies) the sample and refer-
ence DNAs with Cy5 and Cy3, respectively. The labeled
DNA was mixed with 25 μg of Cot-1 DNA (Invitrogen),
denatured at 95°C for 3 minutes, and incubated at 37°C
for 30 minutes. The probe mixture was then hybridized
for 40 hours at 65°C (G4450A; SurePrint G3 Human
CGH Microarray Kit 8x60K; Agilent Technologies). After
washing the array, it was scanned (G2565BA Microarray
Scanner; Agilent Technologies) and the fluorescent sig-
nals were acquired (Feature Extraction Software; Agilent
Technologies). The ADM-2 algorithm included in Geno-
mic Workbench Software (version 6.0; Agilent Technolo-
gies) was used to identify copy-number alterations
(reference genome: hg 18, threshold = 5.0, minimum
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number of probes = 3 continuous probes, minimum
average of log2 ratio = 0.5). Because the sex chromo-
somes are strictly controlled through epigenetic mechan-
isms, they were excluded from this analysis. The Gene
Expression Omnibus accession number of the microarray
data is GSE33685.
Methyl-CpG binding domain sequencing
High-throughput sequencing of methylated DNA
enriched with methyl-CpG binding domain (MBD) pro-
tein (MBD-seq) was performed as follows. Methylated
DNA was enriched from 0.5 to 2 µg of genomic DNA
obtained from 9 MM, 3 MGUS and 3 NPC specimens
(MethylaMiner™Methylated DNA Enrichment Kit; Life
Technologies Corp., Carlsbad, CA, USA) according to
the manufacturer’s instructions. We then prepared a
fragment library (SOLiD Fragment Library Construction
Kit; Life Technologies) and performed deep sequencing
(SOLiD™3 Plus system; Life Technologies). The
sequenced reads were mapped onto the human genome
(UCSC hg18) using Bowtie software [28].
The number of sequence reads between a pair of
sequential aCGH probe sets was counted and then divided
by the distance between the probes to obtain the average
number of sequence reads per nucleotide. To exclude bias
due to intragenomic variation in mapping efficiency, the
number of average sequence reads was normalized to the
number of sequence reads obtained from control (input)
samples to which MBD protein was not applied. We
defined that value as the average DNA methylation level.
In addition, to exclude bias due to interchromosomal var-
iation caused by copy-number aberrations, the average
DNA-methylation levels were normalized to the copy
numbers of the respective loci obtained from aCGH.
Because the normalized average methylation-level data fol-
lowed a log-normal distribution, they were log-transposed
and statistically standardized.
Statistical analysis
Differences in mean methylation levels between groups
were tested using t-tests (for two groups) or ANOVA with
a post hoc Games-Howell test (for more than two groups).
Pearson’s correlation coefficients were calculated to evalu-
ate the correlations between two continuous variables. For
correlation analysis, log transformation was performed to
normalize the number of aCGH probes. Unsupervised
hierarchical clustering of the samples using the aCGH
results was performed(Cluster 3.0,; originally developed by
Michael Eisen, Stanford University). Densities of the repe-
titive elements were compared using the Mantel-Haenszel
test for linear associations. The linear trend of the methy-
lation levels with categorical values were tested using poly-
nomial contrast in general linear models. To evaluate the
overall survival (OS) of patients with MM, Kaplan-Meier
curves were constructed and evaluated using the log-rank
test, and Cox regression was performed. Values of P<0.05
were considered statistically significant. Because most vari-
ables in this study were inter-associated (e.g., chromoso-
mal aberration status), we did not perform the adjustment
for multiple comparisons. All statistical analyses were per-
formed using SPSS Statistics software (version 20 IBM;
SPSS Inc., Chicago, IL, USA).
Results
Hypomethylation of repetitive elements in MM and MGUS
The demographic and clinical characteristics of the sub-
jects in this study have been summarized (see Additional
file 1, Table S1). We initially performed bisulfite pyrose-
quencing to assess the methylation levels of four repeti-
tive elements, LINE-1, Alu Yb8, Alu Ya5, and Sat-a, in
plasma cells from MM and MGUS samples and from
NPC samples (see Additional file 2, Table S2; see Addi-
tional file 4, Figure S1). As shown in Figure 1A, the mean
levels of repetitive-element methylation were generally
lower in MM than in MGUS, and the level in MGUS was
lower than in NPC. These observations suggest that repe-
titive-element methylation declines progressively during
tumorigenesis. In addition, we found that there were
strong positive correlations between the methylation
levels of the four repetitive elements tested (see Addi-
tional file 3, Table S3), and that the strongest correlation
was between the methylation level of LINE-1 and that of
the other three elements (Figure 1B).
Association between repetitive-element methylation and
chromosomal aberrations
We next used aCGH to analyze copy-number alterations
in 67 MM and 6 MGUS samples, and assessed their asso-
ciation with the level of repetitive-element methylation
(Figure 2A). Consistent with earlier reports, losses on
chromosome 13 and gains on chromosome 19 were preva-
lent among the MM samples (40 to 50%), which con-
firmed the reliability of our analysis. In addition, loss of
the chromosomal arms 1p, 14q, and 22q were also fre-
quently observed in MM. After using unsupervised hier-
archical clustering analysis to classify the MM and MGUS
samples into several subclasses (Figure 2B), we found that
subclasses with prevalent copy-number losses seemed to
be associated with hypomethylation of the repetitive ele-
ments. By contrast, the MGUS samples and other MM
sample subsets were characterized by fewer copy-number
alterations and by a lack of repetitive-element hypomethy-
lation (see Figure 2; note the contrast between samples
with a blue bar and those with a pink bar in the middle of
the figure).
We then examined the association between the respec-
tive chromosomal aberrations and the levels of repetitive-
element methylation. If there were more than 50 probe
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sets within a copy-number gain or loss region on the same
chromosome arm, we defined it as a chromosomal gain or
loss, respectively (see Additional file 5, Figure S2A). Using
this approach, we found that loss of 13q, which was the
most marked chromosomal aberration, frequently coin-
cided with other chromosomal losses (see Additional
file 5, Figure S2B). Samples showing a loss of 13q and
those with a loss of any chromosomal arm showed signifi-
cantly lower levels of LINE-1 methylation than those with-
out such losses (Figure 3A). We also found an association
between global LINE-1 hypomethylation and gain or loss
on the respective chromosomal arms (summarized as a
volcano plot in Figure 3B). As highlighted in Figure 3B, we
found significant associations between global LINE-1
hypomethylation and loss of 22q, 1p, 16q, and 14q
(see Additional file 5, Figure S2C). We also observed a
tendency for other chromosomal losses to associate posi-
tively with LINE-1 hypomethylation, and similar results
were obtained with other repetitive elements (see Addi-
tional file 5, Figure S2D).
To quantify the degree of copy-number aberration, we
determined for each tumor the number of aCGH probes
within copy-number gain or loss regions, and compared
that to the level of LINE-1 methylation. In this analysis,
the probe number was used as a surrogate for the degree
of global genomic alteration. Notably, we found a strong
inverse correlation between the numbers of losses found
by the probes and the LINE-1 methylation levels, whereas
the gains did not show this tendency (Figure 3C). Similar
results were obtained for other repetitive elements, but the
correlations were weaker than those for LINE-1 (see Addi-
tional file 5, Figure S2E).
LINE-1 density and genomic vulnerability to global
hypomethylation
We next focused on the relationship between genomic
breakpoints at particular loci and global LINE-1 methyla-
tion. Our emphasis on LINE-1 methylation reflected the
fact that LINE-1 showed the strongest association with
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Figure 1 Quantitative analysis of repetitive-element methylation in malignant melanoma (MM). (A) Results of quantitative methylation
analysis of the indicated repetitive elements in normal plasma cells (NPC; n = 4), monoclonal gammopathy of undetermined significance (MGUS;
n = 7) and MM (n = 74). *P < 0.05, **P < 0.01 and ***P<0.001. (B) Scatter plots for correlating percentage long interspersed nuclear element-1
(LINE-1) methylation levels with those of the indicated repetitive elements. Pearson’s correlation coefficients with regression lines and their 95%
confidence intervals are shown on the plots.
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elements we examined in this study. Because the bound-
aries of regions with copy-number losses are thought to
be responsible for particular genomic breaks, we defined
breakpoints as regions encompassed by a pair of probe
sets located inside and outside the boundary of the loss
(Figure 3D). In addition to the number of probes within
copy-number loss regions, the total numbers of break-
points in the respective samples were significantly and
inversely correlated (R = -0.360, P = 0.003) with the
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Figure 2 Genome-wide copy-number analysis in malignant melanoma (MM) and its association with repetitive-element methylation.
(A) Summary of the results of array comparative genomic hybridization (aCGH) analyses in MM (n = 67) and monoclonal gammopathy of
undetermined significance (MGUS; n = 6). Loss frequencies(green) are shown on the left, and gain (orange) on the right. (B) Unsupervised
hierarchical clustering of the MM and MGUS samples using the aCGH data. Color scales represent genomic loss (green), gain (orange) and no
change (light blue) in copy number. The heat map shown underneath indicates the methylation levels of the indicated repetitive elements.
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Figure 3 Association between levels of long interspersed nuclear element-1 (LINE-1) methylation and chromosomal aberrations in
malignant melanoma (MM). (A) comparison of LINE-1 methylation levels between MMs with and without loss of (left) 13q (n = 28 and 39,
respectively) and (right) any chromosome arm (n = 36 and 31, respectively). Each dot represents the level of LINE-1 methylation in a single
tumor. The average methylation levels and P values are shown underneath. (B) Volcano plot showing the relationship between changes in LINE-
1 methylation and chromosomal aberrations. Each dot represents a chromosomal arm. Differences in the average levels of LINE-1 methylation
between tumors with and without aberrations in the indicated chromosomal arms (loss in green and gain in red) are plotted on the horizontal
axis, and P values for the respective comparisons are plotted on the vertical axis. Chromosomal arms in which loss exhibited a significant
association with LINE-1 hypomethylation (P < 0.05) are highlighted. (C) Scatter plots showing the correlations between the numbers of array
comparative genomic hybridization (aCGH) probes in the gained or lost regions and LINE-1 methylation levels in MMs, with regression lines and
their 95% confidence intervals. Note that the numbers of probes in the lost regions showed a significant inverse correlation with the LINE-1
methylation levels. (D) Schematic diagram of the putative breakpoints. Green lines indicate aCGH probe sets within lost regions, while blue lines
indicate those within intact genomic regions. Light green and light blue areas represent lost and intact genomic regions, respectively.
Breakpoints (pink) were defined as regions encompassed by a pair of probe sets located at the boundary of the genomic lost regions. (E) Scatter
plot showing the correlations between the numbers of breakpoints and LINE-1 methylation levels in MMs, with the regression line and its 95%
confidence interval. Note that the numbers of breakpoints showed a significant inverse correlation with the LINE-1 methylation levels.
(F) Frequencies of the indicated LINE-1 densities (0, 0.01 to 13.43, 13.44 to 26.35, 26.36 to 39.99 and ≥40.00 per 100,000 bp) at the common
breakpoints (CBPs, n = 80) and across the whole genome. Note that CBPs were significantly associated with higher LINE-1 densities.
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80 common breakpoints (CBPs) present in 4 (5%) of 67
MM cases (Table 1) To assess the relationship between
the distribution of LINE-1 and genomic breaks, we used
RepeatMasker (Institute for Systems Biology; UCSC Gen-
ome Bioinformatics Site [29] to assess LINE-1 density at
the respective CBPs. The densities were then categorized
into five groups according to their distribution across the
entire genome (0, 0.01 to 13.43, 13.44 to 26.35, 26.36 to
39.99, and ≥40.00 per 100,000 bp). Interestingly, the
results (summarized in Figure 3F) showed that the aver-
age LINE-1 density at CBPs (n = 80) was significantly
higher than the average density over the entire genome
(28.2 in the whole genome vs. 34.4 in the CBPs per
100,000 bp; P = 0.025). By contrast, there was no clear
correlation between the density of Alu sequences and
CBPs (see Additional file 6, Figure S3A).
In addition, although the involvement of physiological
class-switch rearrangements could not be ruled out in our
experiments, we noted several CBPs within the IGH locus
at 14q32.33, which is known to be a scaffold for distinctive
translocations in MM (e.g., t(11;14)(q13;q32) and t(4;14)
(p16;q32)). Consistent with the findings described above,
we observed significantly greater LINE-1 density in the
IGH locus than in the neighboring genomic regions (P <
0.001) (see Additional file 6, Figures S3B,C).
Lower methylation levels at common breakpoints and
LINE-1-dense regions in MM
To evaluate whole-genome DNA methylation, we next
performed MBD-seq for nine MM, three MGUS and three
NPC samples [28]. We found that, in MM samples,
methylation levels at CBP regions were significantly lower
than across the whole genome (Figure 4A). By contrast,
we found no such differences in MGUS, while NPC sam-
ples showed somewhat higher methylation at CBP regions
(Figure 4A). These observations suggest that average
DNA-methylation levels at CBP regions decline progres-
sively during tumorigenesis.
We next stratified genomic regions according to their
LINE-1 densities, and calculated the average methylation
levels in the respective categories. We observed an inverse
relationship between methylation levels and LINE-1 densi-
ties in MM, whereas methylation levels and LINE-1 densi-
ties were positively correlated in MGUS, and this tendency
was even clearer in NPC (Figure 4B). These observations
again support our hypothesis that methylation levels in
LINE-1-enriched regions decline during the development
of MM.
When we assessed the methylation levels at break-
points in respective samples, we observed that all but one
MM sample showed reduced methylation at the sample-
specific breakpoints, which is not consistent with the
observations summarized above (Figure 4C, MM3 and
MM7). Interestingly, however, one sample (MM4)
showed frequent genomic breaks (133 breakpoints) with
higher methylation levels at the breakpoints (Figure 4C).
We also found that the sample-specific breakpoints in
MM4 were not associated with higher LINE-1 density,
which was different from the majority of MM samples
(Figure 4D). Collectively, our results suggest that higher
LINE-1 densities and hypomethylation are significantly
associated with breakpoints in the majority of MM sam-
ples, while a subset of samples do not follow this pattern
(the small number of exceptional samples are shown in
Figure 3C,E).
Locus-specific LINE-1 methylation correlates with global
LINE-1 methylation
To confirm that the global methylation levels determined
by our bisulfite pyrosequencing truly reflect the methyla-
tion status at the respective loci, we next performed locus-
specific bisulfite pyrosequencing at selected LINE-1 loci.
We first analyzed the 5’ untranslated region (UTR) of a
LINE-1 sequence in one of the CBPs on chromosome
12p13.2; genomic alterations are commonly observed in
this area in hematological malignancies (see Additional
file 7, Figures S4A, B; see Additional file 2, Table S2). In
addition, we analyzed a second 5’ UTR of a LINE-1 in a
non-breakpoint region on chromosome 12q21.1. In both
assessments, we observed a significant positive correlation
between local and global LINE-1 methylation levels
(Figure 4E), and also between the two local LINE-1 methy-
lation levels (see Additional file 7 Figure S4C). By contrast,
methylation levels in the gene body region of LINE-1
(ORF2) at 12p12.3 were consistently high in most samples,
and did not correlate with global LINE-1 methylation
levels (Figure 4F). Because global methylation was also
assessed at the 5’ UTR of LINE-1 (see Additional file 4,
Figure S1A), these results confirmed that global hypo-
methylation during the development of MM is closely
associated with reduced methylation levels at respective
LINE-1 loci.
Association of LINE-1 hypomethylation with a poor
prognosis in MM
Finally, we examined the association between LINE-1
methylation and prognosis in MM. We first determined
the LINE-1 methylation-level that most optimally distin-
guished between individuals who did and did not survive.
We found this to be 36.0%, which was the closest point
to the left upper corner of the receiver operating charac-
teristic curve. We then divided all the patients with MM
into two groups: those above and below that level. When
we compared the survival rates in the two groups, we
found that OS from time of sample collection and OS
from time of initial diagnosis were both significantly
shorter for patients with lower levels of LINE-1 methyla-
tion (Figure 5A; see Additional file 8, Figure S5A).
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Table 1 List of common breakpoints
Chr. Locus Start End LINE-1 density
(per 100,000 bp)
Gene Break frequency, % Chr. Locus Start End LINE-1 density
(per 100000bp
Gene Break frequency, %
1 p34.2 41313735 41355091 58.03 SCMH1 10.4 10 q25.1 111391808 111534660 37.1 6.0
1 p34.2 41479154 41520306 21.87 11.9 10 q25.3 116921563 116965495 106.98 ATRNL1 10.4
1 p31.3 63102450 63125693 25.81 9.0 10 q25.3 117395507 117462466 37.34 ATRNL1 9.0
1 q21.1 145031426 145108225 54.69 PRKAB2 6.0 11 p13 36266146 36292214 57.54 6.0
2 p23.2 27659776 28122129 48.23 BRE 6.0 11 q23.3 117486844 117510539 84.41 SCN4B 14.9
2 p15 63302135 63367996 65.29 C2orf86 9.0 12 p13.2 11222379 11312714 55.35 PRB3 6.0
2 p11.2 88925032 88984458 53.85 6.0 12 p12.3 15020696 15041656 57.25 7.5
2 q11.2 96394039 96423431 47.63 13.4 12 p11.21 30798016 30861280 41.1 9.0
2 q14.2 118022882 119843354 27.52 DBI 7.5 12 q12 34236852 36858944 7.09 6.0
3 p24.2 25637260 25664255 25.93 TOP2B 16.4 12 q13.2 53311891 53382664 35.32 16.4
3 p24.2 25799317 25810811 8.7 OXSM 10.4 12 q13.2 54253884 54290994 40.42 13.4
3 p24.2 25810870 25997134 29.53 10.4 12 q14.1 56621139 56633663 7.98 XRCC6BP1 9.0
3 q11.2 90336752 95063426 1.23 6.0 12 q21.33 90946754 91022602 21.09 7.5
3 q26.1 163874118 163997228 33.3 47.8 13 q14.11 43044213 43114392 45.6 ENOX1 11.9
4 q23 99907678 100011201 56.99 6.0 13 q14.11 43114451 43143651 10.27 ENOX1 11.9
4 q31.3 152038958 152092912 48.19 LRBA 7.5 14 q22.1 48984150 49093570 25.59 6.0
4 q31.3 153097317 153228047 17.59 7.5 14 q31.3 88397409 88411102 51.12 TTC8 9.0
4 q34.1 174459916 174490317 23.03 HMGB2 6.0 14 q32.33 105080399 105354886 21.86 IgH 19.4
5 q13.3 75888651 75947525 25.48 IQGAP2, F2RL2 7.5 14 q32.33 105469384 105481523 57.67 IgH 11.9
14 q32.33 105787449 105834932 86.35 IgH 9.0
5 q13.3 76284777 76301015 0 CRHBP 7.5 14 q32.33 105947052 105977946 61.5 IgH 16.4
5 q31.3 140094857 140166875 59.71 PCDHA1/2/3 7.5 15 q22.2 59803190 59933103 24.63 VPS13C 6.0
5 q33.3 157216334 157301114 41.28 9.0 15 q24.3 74558533 74601045 56.45 SCAPER 9.0
5 q34 162798715 162800093 0 CCNG1 9.0 16 q11.2 34083801 45122058 2.98 FLJ43980 6.0
5 q34 162818326 162833628 19.61 HMMR 11.9 17 q12 35221880 35241893 9.99 IKZF3 11.9
5 q35.1 170161782 170195254 8.96 7.5 17 q12 35282145 35316098 55.96 GSDMB 16.4
5 q35.1 170596026 170659586 33.04 RANBP17 6.0 17 q21.2 36666037 36724675 28.99 KRTAP17-1 6.0
6 q11.1 62760108 62854732 38.05 KHDRBS2 9.0 17 q21.31 38255982 38261676 17.56 AOC3 7.5
6 q26 162822332 162896532 9.43 PARK2 7.5 17 q25.1 71511380 71527979 0 EVPL 6.0
6 q27 166369554 166405962 52.19 7.5 19 q13.12 40328372 40338038 0 FXYD5 7.5
7 p15.3 20788779 20857393 14.57 6.0 19 q13.42 61045704 61062298 66.29 NLRP4 20.9
7 p14.1 39890729 39952510 58.27 6.0 20 p13 3365914 3411271 59.53 ATRN 9.0
7 p14.1 40008069 40034702 45.06 CDC2L5 6.0 20 p13 3553255 3588125 43.02 GFRA4 9.0
7 q31.2 116015401 116093417 15.38 11.9 20 q12 40298330 40332059 0 PTPRT 22.4
7 q35 147108655 147152043 27.66 CNTNAP2 6.0 20 q13.12 43765836 43768958 0 WFDC13 6.0
8 q12.1 59427474 59488208 41.16 UBXN2B 7.5 20 q13.32 57813291 57856200 9.32 9.0
8 q12.1 59519371 59565778 15.08 CYP7A1 7.5 20 q13.33 58011342 58074892 33.04 C20orf197 7.5
8 q24.3 145297206 145464363 45.47 BOP1 13.4 21 q22.11 31050355 31088151 10.58 6.0
9 p23 11563590 11687635 54.01 6.0 22 q11.22 21520273 21588229 38.26 IgL 6.0
9 q21.33 87357577 87392381 51.72 AGTPBP1 9.0 22 q12.3 34602119 34638273 0 RBM9 6.0
10 q25.1 109269991 109444702 43.5 6.0
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Figure 4 Association between long interspersed nuclear element-1 (LINE-1) densities and methylation levels in malignant melanoma
(MM). (A,B) Average levels of DNA methylation determined by methyl-CpG binding domain sequencing (MBD-seq) analysis in normal plasma
cells (NPC; n = 3), monoclonal gammopathy of undetermined significance (MGUS; n = 3) and MM (n = 9) for (A) the whole genome and at the
common breakpoints (CBPs, n = 80) and (B) the respective LINE-density regions. Correlation coefficients are shown above the box plots. ***P <
0.001. Note that average methylation levels were inversely correlated with the LINE-1 densities in MM, while they were positively correlated in
NPC. (C) Average DNA-methylation levels at the sample-specific breakpoints in representative MM cases. Sample names and global LINE-1
methylation levels are indicated underneath, and the number of breakpoints in each sample is also indicated. Note that LINE-1 methylation
levels at sample-specific CBPs were significantly downregulated in samples with global LINE-1 hypomethylation (MM3 and MM7), whereas MM4
exhibited the inverse pattern. (D) Frequencies of the indicated LINE-1 densities (0, 0.01 to 13.43, 13.44 to 26.35, 26.36 to 39.99 and ≥40.00 per
100,000 bp) at the sample-specific breakpoints and across the whole genome in three MM cases. Samples with global LINE-1 hypomethylation
showed higher LINE-1 densities at the breakpoints (MM3 and MM7), while a sample without global hypomethylation (MM4) did not show that
tendency. (E) Correlations between the levels of methylation of selected LINE-1 loci and those of global LINE-1 in MM samples (n = 73).
Methylation in the 5’ untranslated region (UTR) of a LINE-1 located at a CBP region on 12p13.2 is shown on the left and that of another LINE-1
located at a non-breakpoint region on 12q21.1 is shown on the right. Pearson’s correlation coefficients with regression lines and their 95%
confidence intervals are shown on the plots. ***P < 0.001. (F) There was no correlation between methylation levels within the gene body region
of a selected LINE-1 and global LINE-1 methylation levels in MM samples (n = 73). Methylation levels in open reading frame 2 (ORF2) of a LINE-1
located at 12p12.3 were compared with global LINE-1 methylation in MM (n = 73). Pearson’s correlation coefficient with regression line and its
95% confidence interval are shown on the plot.
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We also found that global LINE-1 methylation level
tended to be inversely correlated with stage according to
the International Staging System (ISS) (P for trend =
0.078; ISS stage 1, 44.7%; stage 2, 41.6%; stage 3, 38.4%).
To exclude any effect of different clinical stages for
patients, we stratified the samples into two groups: those
with ISS stage 1 MM, and those with stage 2 or 3 MM.
Even after adjusting for clinical stage, patients with
LINE-1 hypomethylation showed significantly poorer OS
(Figure 5B). In addition, after adjustment for other prog-
nostic factors, including age, sex, ISS, and loss of chro-
mosome 13 (with stratification by center), LINE-1
hypomethylation was still independently associated with
a poor prognosis (hazard ratio = 3.9, P = 0.028; Addi-
tional file 8, Figure S5B). We also evaluated the associa-
tions of Alu Yb8, Alu Ya5, and Sat-a hypomethylation
with prognosis, but these were not as strongly associated
as LINE-1 hypomethylation (see Additional file 8, Figure
S5C). Although a weak association was observed between
Alu Ya5 hypomethylation and shorter OS, it was not sta-
tistically significant after adjustment for the other prog-
nostic factors (hazard ratio = 1.7, P = 0.430).
Discussion
In this study, we analyzed the DNA methylation of sev-
eral representative repetitive elements: LINE-1, Alu, and
Sat-a. LINE-1 is an abundant retrotransposon that
makes up approximately 20% of the mammalian genome.
It encodes a reverse transcriptase and is able to amplify
and transpose itself within the genome. Alu is one of the
short interspersed elements that comprise approximately
10% of the total DNA. Alu does not encode a functional
protein, but depends on the machinery of active LINE-1
for transposition [30,31]. Sat-a is a member of the tan-
demly repeated sequence family, members of which are
located at the centromeres of all primate chromosomes
[32]. Their presence and spread cause several inherited
diseases through the induction of genomic diversity
Log rank test  P = 0.015 
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Figure 5 Association of long interspersed nuclear element-1 (LINE-1) methylation level with prognosis in malignant melanoma (MM).
(A, B) Kaplan-Meier curves for overall survival for patients with MM, with samples stratified based on (A) LINE-1 methylation levels and
(B) International Staging System stage. The P-value and hazard ratio (HR) are also shown.
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[21,33]. To avoid their inappropriate activation, tran-
scription of repetitive elements is regulated by epigenetic
mechanisms, including DNA methylation [21]. Dysregu-
lation of repetitive elements, especially LINE-1, due to
hypomethylation, has recently been observed in various
tumors [24-27,34-37]. Moreover, insertion of LINE-1
leads to activation of several oncogenes [38,39]. We
found strong positive correlations between methylation
levels of the all repetitive elements analyzed including
local-specific LINE-1 (Figure 1A; see Additional file 3,
Table S3, Figure 4E), which suggests the existence of a
key factor inducing global hypomethylation of repetitive
elements.
Methylation within the promoter regions of protein-cod-
ing genes has been found to be generally lower in MM
than MGUS or NPC [15,16], and it declines progressively
during malignant progression in plasma cells. In the pre-
sent study, we found a similar decline in the methylation
of repetitive elements in MGUS and MM samples. Bollati
et al. also observed lower levels of repetitive-element
methylation in MM, but they did not analyze methylation
levels in MGUS [40]. Reduced methylation of repetitive
elements has also been reported in precancerous lesions in
various organs [41,42], suggesting that global hypomethy-
lation is an early event during tumorigenesis in a number
of malignancies. Although methylation of repetitive ele-
ments was generally down-regulated in MM compared
with NPC, there was substantial case-to-case variability,
and the level of methylation, especially of LINE-1, was
strongly associated with the degree of copy-number loss
and genomic breaks. Similar findings have been reported
for other types of malignancy, suggesting that global hypo-
methylation is associated with chromosomal instability
[26,27,35,36]. Consistent with that idea, recent evidence
suggests that hypomethylation-induced activation of repe-
titive elements is directly associated with the chromosomal
instability seen in cancer [21,38,39,43,44]. In the context of
those earlier reports, our findings indicate that, in malig-
nant cells, LINE-1 may be more active and exhibit a
greater potential to induce genomic alterations than other
repetitive elements.
We found that LINE-1 density was greater at the 80
CBPs than elsewhere, which suggests that hypomethyla-
tion of LINE-1 may be an important factor affecting
genomic breaks. For example, the 14q32.33 locus, which
exhibits frequent chromosomal translocations and rear-
rangements in MM and shows very high LINE-1 density,
is a site that exhibits possible vulnerability in MM. Con-
ceptually similar to the CBPs described in this study,
common fragile sites (CFSs) are highly unstable regions
of the genome [45]. Our data indicate that one well-
known CFS, FRA6E/PARK2, is located at chromosome
6q26 [46], and the surrounding area is also a CBP in
MM. A number of CFSs are reportedly located in regions
in which there is a high density of both repetitive ele-
ments and CBPs [47,48]. In addition, genomic loci at
12p13, where we investigated local LINE-1 methylation
levels and which is a CBP, are frequently deleted, and are
associated with a poor prognosis in MM [49]. Chromoso-
mal aberrations at 12p13 have also been reported in
other types of hematological malignancy [50]. We also
identified two CBPs at 13q14, a critical region that is
often deleted in MM and other lymphoid disorders, and
in which enrichment of LINE-1 and repetitive elements
has been reported [51].
Our results demonstrate that DNA-methylation levels at
CBPs and regions with high LINE-1 densities decline dur-
ing the development of MM. Detailed analysis of selected
LINE-1 loci revealed that reductions in methylation within
the 5’ UTR, but not the gene body region, were signifi-
cantly associated with global hypomethylation. These
results indicate that hypomethylation in the 5’ UTR of
LINE-1 at CBP regions is deeply involved in the develop-
ment of MM. However, our findings may not support a
simple hypothesis that hypomethylation at LINE-1 loci is a
determinant of genomic vulnerability at that position,
because methylation levels of both CBP-associated and
CBP-independent LINE-1 loci positively correlated with
global methylation. Collectively, our results suggest that
both higher LINE-1 density and hypomethylation in the 5’
UTR may be critical factors inducing genomic vulnerabil-
ity in MM. By contrast, we also observed that a small
number of MM cases exhibited frequent genomic breaks,
despite relatively high global LINE-1 methylation levels.
These cases may be indicative of an underlying mechan-
ism other than LINE-1 hypomethylation, and further
study will be needed to understand the complexity of
genomic vulnerability in malignant cells.
In addition to LINE-1, Sat-a is reportedly hypomethy-
lated and transcriptionally active in various tumors
[23,52]. Although we found the strongest correlation
between copy-number aberrations and LINE-1 hypo-
methylation, further investigation of the significance of
other repetitive elements is needed. We observed a stron-
ger association between repetitive-element methylation
and chromosomal aberrations than did Bollati et al. in
their earlier study [40]. This may be attributable to differ-
ences in the technologies used to detect copy-number
alterations; whereas we performed aCGH that was spe-
cialized for comprehensive and sensitive genomic analy-
sis, Bollati et al. used fluorescence in situ hybridization to
detect specific chromosomal aberrations.
Although we demonstrated a novel association between
the density and hypomethylation of LINE-1 and genomic
alterations in MM, there are several limitations to this
study. First, the number of benign control samples was
small, and as a result, the statistical power was not suffi-
cient to find significant associations. Second, because we
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could not obtain control samples of normal DNA from
the patients with MM, our results may have been par-
tially influenced by inter-individual copy-number varia-
tions. In addition, as described above, we could not rule
out the involvement of physiological class-switch rearran-
gements at the IGH locus. Third, and most importantly,
because a longitudinal study was not performed to ana-
lyze the molecular changes during the development and
progression of MM, the direct causal relationship
between LINE-1 hypomethylation and genomic vulner-
ability remains to be validated in a future functional
study.
Despite the aforementioned limitations, we found that
LINE-1 hypomethylation is associated with a poor prog-
nosis in MM. Even after stratification and adjustment for
several confounders, the association remained statistically
significant, suggesting LINE-1 hypomethylation as an
independent prognostic factor. Moreover, our findings are
consistent with similar results obtained in other malignan-
cies, and is supported by several reports in which a poorer
prognosis was observed in MM with non-hyperdiploidy
[23,25,36,37].. Our data suggest that non-hyperdiploidy,
which is indicative of genomic and chromosomal loss, is
associated with LINE-1 hypomethylation [3].
Conclusions
Our findings suggest that global hypomethylation of
repetitive elements may increase the malignant potential
of myeloma cells by inducing broad copy-number losses.
In particular, LINE-1 is a probable contributing factor
for chromosomal aberrations and the progression of
MM under conditions of global hypomethylation. Our
results also indicate that clinical management should
include analysis of repetitive-element methylation. For
further investigation, we plan a detailed functional study
to clarify the cause of global hypomethylation and the
precise mechanism of hypomethylation-mediated geno-
mic breaks in MM.
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Additional file 1: Table S1. Demographic and clinical characteristics of
the subjects in this study.
Additional file 2: Table S2. Primer information.
Additional file 3: Table S3. Comparison of the methylation levels and
correlation of the repetitive elements.
Additional file 4: Figure S1. Schematic representations of the repetitive
elements and CpG sites analyzed in this study. Regions amplified by PCR
and analyzed by pyrosequencing are shown underneath the structures.
Additional file 5: Figure S2. (A) Summary of probe numbers included
in gain/loss regions in each chromosome arm of malignant melanoma
(MM) cases. The X-axis represents the probe number and the Y-axis
represents the frequency. The bimodal distribution pattern indicates that
chromosome arms are largely divided into two groups, those with a
smaller number of aberrations (less than 50 probes) and those with a
larger number of aberrations (more than 50 probes). (B) Summary of
chromosomal losses (green) in MM (n = 67); note that the majority of
MMs showing any chromosomal loss showed a loss of 13q. (C)
Comparisons of long interspersed nuclear element-1 (LINE-1) methylation
levels between MMs with and without loss of 1p, 14q, or 16q. (D)
Volcano plots showing the relationship between changes in the
methylation of the indicated repetitive elements and chromosomal
aberrations. Each dot represents a chromosomal arm, and differences in
the average methylation levels between tumors with and without
aberrations (losses are in green, gains are in red) in the arms of interest
are plotted on the horizontal axis, with P values plotted on the vertical
axis. (E) Scatter plots showing the correlations between the numbers of
array comparative genomic hybridization (aCGH) probes in the gain/loss
regions and the levels of methylation of the indicated repetitive
elements. Note that for all of the repetitive elements analyzed, the
degree of deletion inversely correlated with methylation level.
Additional file 6: Figure S3. (A) Frequencies of the indicated Alu
densities (0, 0.01 to 13.43, 13.44 to 26.35, 26.36 to 39.99 and ≥40.00 per
100,000 bp) in the whole genome and common breakpoints (CBPs, n =
80). Note that CBPs were not significantly associated with Alu densities (P
= 0.254). (B) Frequencies of the respective long interspersed nuclear
element-1 (LINE-1) densities in the immunoglobulin heavy chain (IGH)
locus and other loci at 14q32,33 (***P < 0.001). (C) Schematic
representation of the 14q32.33 region. LINE-1 densities are shown on the
top, and the genes are indicated on the bottom.
Additional file 7: Figure S4. Analysis of methylation in selected long
interspersed nuclear element-1 (LINE-1) loci in malignant melanoma
(MM). (A) Summarized results of array comparative genomic
hybridization (aCGH) on chromosome 12 in MM samples (n = 12). Losses
are indicated in green, and common breakpoints (CBPs) at 12p13.3 and
12p12.3 are indicated by red arrows. (B) Locations of primers used in the
locus-specific bisulfite pyrosequencing; shown are original (not bisulfite-
converted) sequences. A non-CBP LINE-1 and two CBP-associated LINE-1
loci were selected and analyzed. Forward primers were located outside
the LINE-1 sequences so that only unique sequences were amplified by
PCR. (C) Correlation between the methylation levels of the 5’
untranslated regions (UTRs) of two local LINE-1s. Pearson’s correlation
coefficients with the regression line and its 95% confidence interval are
shown on the plot.
Additional file 8: Figure S5. (A,B) Kaplan-Meier curves for overall
survival from time of: (A) initial diagnosis for patients with MM stratified
based on long interspersed nuclear element-1 (LINE-1) methylation
levels; (B) sample collection for patients with MM after stratification
based on the presence or absence of 13q deletion; and (C) initial
diagnosis for patients with MM stratified based on the levels of
methylation of the indicated repetitive elements.
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